Skip to content
Search

Latest Stories

'Give me a proper test' as Conor Benn challenges Amir Khan

THE undefeated Conor Benn has challenged Amir Khan after his ruthless one minute and 22 seconds victory over Samuel Vargas at the Copper Box Arena on Saturday (10) night.

But Khan says a fight against Benn would not "make sense" without a world title at stake in the domestic clash.


"Give me a proper test," Benn told Sky Sports. "Give me Amir Khan. I know he's too busy on reality shows and all that. But listen, if he wants it, he can get it."

Khan said the British welterweight first needs to win a major title and has a long way to go.

"Conor well done. Great kid, wish him the best.

"At his age I was a world champ.

"Maybe if he had some belts that fight would make sense but he's got a long way to go yet," Khan tweeted.

Meanwhile, promoter Eddie Hearn said he would want Khan back in the ring soon and make this fight happen.

"Conor Benn against Amir Khan is probably one of the easiest fights to sell, I'll ever take part in," Hearn told Sky Sports.

"What an intriguing fight. A young kid coming up, as you can tell, is rather amped and charged against a guy that is really at the end of his career and has a fantastic legacy in the sport.

"Whether Amir Khan will say, 'I want to bow out to a young man coming through the ranks like Conor Benn.'

"That's up to him and money will talk in that respect. For me, I want to get him back out as soon as possible," Hearn added.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less